Hydrocortisone 1% cream and sertaconazole 2% cream to treat facial seborrheic dermatitis: A double-blind, randomized clinical trial
| Autor: | Maryam Nasimi, S. Ghale-Baghi, Arghavan Azizpour, Kamran Balighi, Seyedeh Zahra Ghodsi, Maryam Daneshpazhooh |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Sertaconazole 2% cream
medicine.medical_specialty Sertaconazole medicine.drug_class business.industry Dermatology medicine.disease law.invention Double blind 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law Seborrheic dermatitis RL1-803 medicine Corticosteroid 030212 general & internal medicine business Adverse effect Original Research Hydrocortisone medicine.drug |
| Zdroj: | International Journal of Women's Dermatology, Vol 3, Iss 2, Pp 107-110 (2017) International Journal of Women's Dermatology |
| ISSN: | 2352-6475 |
| Popis: | Background: Seborrheic dermatitis (SD) is a chronic dermatitis with periods of remission and relapse that requires long-term treatment. Objective: We compared the efficacy and safety of treatment with sertaconazole with standard corticosteroid medications in adults with facial SD. Methods: In this double-blind, randomized controlled trial, 60 patients with a diagnosis of SD were enrolled. Patients were instructed to apply either sertaconazole 2% cream (30 patients) or hydrocortisone 1% cream (30 patients) twice daily to the affected area of the face. The severity of facial SD was assessed at 0, 2, and 4 weeks of treatment. Secondary efficacy measures included patient assessment of seborrhea, adverse events, and improvement percentage (IP). Results: SD lesions cleared significantly (p < .05) and similarly in both treatment groups (p > .05). Both treatments resulted in significant improvement of SD lesions and the rate of adverse events was similar in both groups. The IP was higher for treatment with hydrocortisone in Week 2 and similar in both groups at the end of the study. Limitations: Limitations include the small number of patients who were recruited for this study and the lack of evaluation of time to relapse. Conclusion: Treatment with topical sertaconazole may be regarded as a substitute for topical corticosteroid medications due to the fewer adverse events and similar efficacy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|